Table 3. Univariable analyses for progression free survival (PFS) and overall survival (OS).
| PFS: | ||||
|---|---|---|---|---|
| HR | 95%CI | p value | ||
| Gender | Male/Female | 1.66 | 0.60–4.63 | 0.322 |
| Age | ≥65/<65 | 0.638 | 0.26–1.55 | 0.314 |
| ECOG PS | 0/1/2 | 2.20 | 0.80–6.04 | 0.251 |
| Tumor location | U/L | 1.84 | 0.58–5.85 | 0.302 |
| M/L | 2.79 | 0.88–8.83 | 0.303 | |
| Lauren classification | Intestinal/Diffuse | 1.25 | 0.53–2.95 | 0.603 |
| HER2 | +/- | 2.46 | 0.71–8.59 | 0.142 |
| Liver metastasis | +/- | 0.84 | 0.32–2.22 | 0.724 |
| Ascites | +/- | 1.04 | 0.44–2.48 | 0.926 |
| Pretreatment NLR | ≥5/<5 | 2.43 | 0.92–6.42 | 0.064 |
| Posttreatment NLR | ≥5/<5 | 3.49 | 1.19–10.3 | 0.015 |
| OS: | ||||
|---|---|---|---|---|
| HR | 95%CI | p value | ||
| Gender | Male/Female | 2.23 | 0.45–11.0 | 0.310 |
| Age | ≥65/<65 | 1.47 | 0.39–5.57 | 0.565 |
| ECOG PS | 0/1/2 | 4.05 | 0.87–18.8 | 0.172 |
| Tumor location | U/L | 2.33 | 0.24–23.1 | 0.469 |
| M/L | 3.51 | 0.40–30.5 | 0.256 | |
| Lauren classification | Intestinal/Diffuse | 1.23 | 0.29–5.16 | 0.779 |
| HER2 | +/- | – | – | – |
| Liver metastasis | +/- | – | – | – |
| Ascites | +/- | 1.54 | 0.38–6.20 | 0.538 |
| Pretreatment NLR | ≥5/<5 | 5.38 | 1.34–21.6 | 0.008 |
| Posttreatment NLR | ≥5/<5 | 14.4 | 3.13–66.7 | <0.001 |
Abbreviations: ECOG PS, the Eastern Cooperative Oncology Group Performance Status; U, Upper; M, Middle; L, Lower.